• Explore /
  • Poster
  • / A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).

A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010).

Abstract Poster

Authors

null

Robert Uzzo

Fox Chase Cancer Center, Philadelphia, PA

Robert Uzzo , Axel Bex , Brian I. Rini , Laurence Albiges , Cristina Suarez , Frank Donaldson , Takashi Asakawa , Christina Schiff , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03024996

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4598)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4598

Abstract #

TPS4598

Poster Bd #

272a

Abstract Disclosures

Similar Posters

First Author: Yuming Zhu

First Author: Maria Pagano

First Author: Ronac Mamtani

First Author: Sylvie Giacchetti